Trials / Completed
CompletedNCT03150875
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial. Additionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI308 | Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial. |
| DRUG | Docetaxel | As 2nd line treatment to subjects with squamous NSCLC |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2023-02-22
- Completion
- 2023-02-22
- First posted
- 2017-05-12
- Last updated
- 2023-02-28
- Results posted
- 2021-06-23
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03150875. Inclusion in this directory is not an endorsement.